Guggenheim Assigned “a Buy” Rating to Protara Therapeutics Inc (NASDAQ:TARA) Stock
Guggenheim raised the price target for the Protara Therapeutics Inc (NASDAQ:TARA) stock to “a Buy”. The rating was released on July 10, 2023, according to finviz. The research report from Oppenheimer has initiated the stock to Outperform, with a price target set at $43. The stock was initiated by Cowen, who disclosed in a research […]
The Protara Therapeutics Inc (TARA) Stock expansion path ahead
Guggenheim raised the price target for the Protara Therapeutics Inc (NASDAQ:TARA) stock to “a Buy”. The rating was released on July 10, 2023, according to finviz. The research report from Oppenheimer has initiated the stock to Outperform, with a price target set at $43. The stock was initiated by Cowen, who disclosed in a research […]
Protara Therapeutics Inc (TARA) Stock: Thought Concerns
Guggenheim raised the price target for the Protara Therapeutics Inc (NASDAQ:TARA) stock to “a Buy”. The rating was released on July 10, 2023, according to finviz. The research report from Oppenheimer has initiated the stock to Outperform, with a price target set at $43. The stock was initiated by Cowen, who disclosed in a research […]
Analysts Rating: Protara Therapeutics Inc (NASDAQ:TARA) Stock Won “a Buy” Rating From Guggenheim
Guggenheim raised the price target for the Protara Therapeutics Inc (NASDAQ:TARA) stock to “a Buy”. The rating was released on July 10, 2023, according to finviz. The research report from Oppenheimer has initiated the stock to Outperform, with a price target set at $43. The stock was initiated by Cowen, who disclosed in a research […]
